Immunotoxin therapy of cancer
โ Scribed by Pastan, Ira; Hassan, Raffit; FitzGerald, David J.; Kreitman, Robert J.
- Book ID
- 109947630
- Publisher
- Nature Publishing Group
- Year
- 2006
- Tongue
- English
- Weight
- 344 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1474-1776
- DOI
- 10.1038/nrc1891
No coin nor oath required. For personal study only.
โฆ Synopsis
Rationally designed anticancer agents that target cell-surface antigens or receptors represent a promising approach for treating cancer patients. However, antibodies that bind these targets are often, by themselves, non-cytotoxic. By attaching potent toxins we can dramatically improve the clinical utility of some anti-tumour antibodies. Here we describe the construction and clinical utility of several recombinant immunotoxins; each of which is composed of antibody Fv fragments fused to powerful bacterial toxins. Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.
๐ SIMILAR VOLUMES
Immunotoxins are composed of a protein toxin connected to a binding ligand such as an antibody or growth factor. These molecules bind to surface antigens (which internalize) and kill cells by catalytic inhibition of protein synthesis within the cell cytosol. Immunotoxins have recently been tested cl